1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors

Details for Australian Patent Application No. 2006235492 (hide)

Owner Abbott Laboratories

Inventors Gandhi, Virajkumar B.; Zhu, Guidong; Penning, Thomas D.; Giranda, Vincent; Gong, Jianchun

Agent Spruson & Ferguson

Pub. Number AU-B-2006235492

PCT Pub. Number WO2006/110816

Priority 60/670,204 11.04.05 US

Filing date 11 April 2006

Wipo publication date 19 October 2006

Acceptance publication date 27 October 2011

International Classifications

C07D 401/04 (2006.01) Heterocyclic compounds containing two or more hetero rings

A61K 31/4184 (2006.01)

A61K 31/454 (2006.01)

A61K 31/55 (2006.01) - having seven-membered rings, e.g. azelastine, pentylenetetrazole

A61P 9/10 (2006.01) Drugs for disorders of the cardiovascular system

C07D 403/04 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

Event Publications

25 October 2007 PCT application entered the National Phase

  PCT publication WO2006/110816 Priority application(s): WO2006/110816

27 October 2011 Application Accepted

  Published as AU-B-2006235492

23 February 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006235495-Variant forms of urate oxidase and use thereof

2006235490-Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents